CeloNova receives expanded indication for benign prostatic hyperplasia

308

CeloNova BioSciences has announced that it has received an expanded indication (CE mark) in Europe for its Embozene embolic microspheres to include the treatment of benign prostatic hyperplasia.

Prostatic artery embolization offers a minimally invasive procedure when compared to the current surgical standard of care, transurethral resection of the prostate that gives men suffering from benign prostatic hyperplasia an important treatment alternative.

Symptoms can include frequent urination, weak urine stream and a persistent feeling of having to urinate. Benign prostatic hyperplasia is a common condition in men, which increases with age. Symptomatic benign prostatic hyperplasia typically occurs in the sixth and seventh decades of a man’s life, reaching an estimated 40% of men in their 70s.

“The symptoms of benign prostatic hyperplasia can cause significant impact in a patient’s quality of life and prostatic artery embolization offers a safe and effective treatment option for men”, said Ulf Teichgraeber, director of Radiology at University Hospital, Jena, Germany.

“The expanded indication in Europe for benign prostatic hyperplasia provides continuing support to interventional radiologists and urologists working in tandem to offer men relief from the symptoms of benign prostatic hyperplasia,” said Jörg Menten, president international of CeloNova BioSciences.

“Embozene microspheres go through a sophisticated manufacturing process that ensures precisely calibrated size and shape,” said Jane Ren, chief technology officer of CeloNova BioSciences.